| |
 |
This
project is focused on increasing and stabilizing the supply of
artemisinin to reduce the cost of life-saving artemisinin-based
combination therapies (ACTs) by lowering the production cost of
artemisinin derivatives. To do this we are using a new technology,
synthetic biology, to produce artemisinin, a natural compound traditionally
extracted from Artemisia
annua,
or the sweet wormwood plant. The project team has developed a
semisynthetic artemisinin
production system, into which the genes from A. annua are being transferred.
The microbes will produce artemisinic acid, a precursor to artemisinin, during
a standard semi-synthetic fermentation process. Artemisinic acid is then chemically
converted to artemisinin using a novel chemistry process. The resulting
production method is unique and powerful in that it will be able to reliably
produce pure artemisinin, which can then be chemically converted into one or
more of its derivatives for incorporation into ACTs, in nearly inexhaustible
supply at an affordable cost. |
| |

The Process for the Production of
Artemisinin. Using synthetic biology, the metabolism
of Escherichia coli (E. coli) is engineered
to produce artemisinic acid, a precursor to the important
antimalarial artemisinin. Starting from acetyl-CoA, an
abundant product of E. coli central metabolism,
the bacteria produce, in turn, mevalonate, farnesyl pyrophosphate
(FPP), amorphadiene and finally, artemisinic acid. The
artemisinic acid is released from the bacteria and purified
from the culture media. The artemisinic acid is then chemically
converted to artemisinin. Once the artemisinin is produced,
it must be further chemically converted into a derivative
such as artesunate or artemether, which is then integrated
into ACTs. The production process to make semisynthetic
artemisinin is expected to take weeks rather than the months
required to grow and extract botanically-derived artemisinin. |
| |
Synthetic Biology |
Synthetic biology is a cutting-edge field of research that combines science and engineering in
order to design and build novel biological systems or to re-design existing systems for useful purposes. In this case, the project team is using synthetic biology to insert genes from the plant A. annua into E. coli, a bacterium. Professor Jay Keasling’s laboratory in the Center for Synthetic Biology at the University of California, Berkeley is completing the synthetic biological process to produce artemisinic acid, a precursor to artemisinin. Berkeley scientists are discovering the metabolic pathway in the wormwood plant and identifying the genes required to make artemisinic acid. Using synthetic biology, they are inserting this pathway into microorganisms to manufacture copious amounts of the precursor. Scientists at Amyris are collaborating with the Center for Synthetic Biology to optimize this semi-synthetic artemisinin strain for commercial production. More information on synthetic biology can be found here. |
| |
Fermentation |
Fermentation refers to the bulk growth of microorganisms such as E. coli in a culture medium containing nutrients. The organisms break down these nutrients using metabolic processes that produce various compounds utilized by the cell. Fermentation has been used for decades to produce foods and beverages, as well as important chemicals and medicines, such as some antibiotics and protein-based pharmaceuticals. In this project, the Keasling lab and Amyris are developing inexpensive processes to begin the scale-up process of fermentation to produce artemisinic acid. In this case the cells produce artemisinic acid as a product of their metabolism, which they release into the culture medium. The artemisinic acid can then be extracted from the medium and purified. |
| |
Chemistry |
Amyris has developed a novel, less expensive chemical process to convert artemisinic acid to artemisinin, thereby completing the synthesis of artemisinin. Traditionally, this chemical conversion is costly and would be extremely difficult to perform at a commercial scale. Amyris has developed a new method that can be scaled-up and integrated into the artemisinin production. Once the artemisinin is produced, it must be further chemically converted into a derivative such as artesunate or artemether, which are then integrated into artemisinin combination therapies (ACTs).
|
|